Mitsuru Sasako

1989–2024 年に発表

117
論文数
30,425
被引用数
87
h 指数
117
i10 指数

被引用数

Mitsuru Sasako の年別被引用数1992 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 3 件1995 年: 被引用 15 件1996 年: 被引用 17 件1997 年: 被引用 13 件1998 年: 被引用 18 件1999 年: 被引用 45 件2000 年: 被引用 56 件2001 年: 被引用 46 件2002 年: 被引用 84 件2003 年: 被引用 62 件2004 年: 被引用 85 件2005 年: 被引用 163 件2006 年: 被引用 159 件2007 年: 被引用 101 件2008 年: 被引用 138 件2009 年: 被引用 123 件2010 年: 被引用 194 件2011 年: 被引用 207 件2012 年: 被引用 177 件2013 年: 被引用 198 件2014 年: 被引用 175 件2015 年: 被引用 190 件2016 年: 被引用 188 件2017 年: 被引用 150 件2018 年: 被引用 113 件2019 年: 被引用 819 件2020 年: 被引用 774 件2021 年: 被引用 584 件2022 年: 被引用 419 件2023 年: 被引用 298 件2024 年: 被引用 525 件2025 年: 被引用 188 件2026 年: 被引用 18 件

引用元

国・地域

この著者を引用した国・地域の世界地図日本: 引用元論文 1,043 件、この内訳の 19.6%中国: 引用元論文 933 件、この内訳の 17.5%アメリカ合衆国: 引用元論文 745 件、この内訳の 14%韓国: 引用元論文 364 件、この内訳の 6.8%イギリス: 引用元論文 252 件、この内訳の 4.7%イタリア: 引用元論文 246 件、この内訳の 4.6%ドイツ: 引用元論文 232 件、この内訳の 4.4%オランダ: 引用元論文 178 件、この内訳の 3.3%フランス: 引用元論文 141 件、この内訳の 2.7%カナダ: 引用元論文 88 件、この内訳の 1.7%スイス: 引用元論文 77 件、この内訳の 1.5%スペイン: 引用元論文 76 件、この内訳の 1.4%
0%19.6%その他 17.8%

分野

  • Medicine86%
  • Biochemistry, Genetics and Molecular Biology9.7%
  • Immunology and Microbiology0.9%
  • Decision Sciences0.8%
  • Engineering0.5%
  • Neuroscience0.5%
  • その他1.6%

トピック

  • Gastric Cancer Management and Outcomes21.7%
  • Gastrointestinal Tumor Research and Treatment8.5%
  • Esophageal Cancer Research and Treatment7.1%
  • Helicobacter pylori-related gastroenterology studies5.5%
  • Metastasis and carcinoma case studies4.5%
  • Esophageal and GI Pathology1.8%
  • その他50.9%

共著者

全論文

検索で開く
  1. Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

    著者: , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 1,475

  2. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2007 被引用: 2,520

  3. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

    著者: , , , , - The Lancet Oncology 2010 被引用: 1,785

  4. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria

    著者: , , , , , , , , , , - Surgery Today 2015 被引用: 782

  5. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 700

  6. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2019 被引用: 320

  7. D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer

    著者: , , , , , , , , , , , - New England Journal of Medicine 2008 被引用: 1,021

  8. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912

    著者: , , , , , , , , , , , , , , , - Gastric Cancer 2016 被引用: 391

  9. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Zander, Hakan Alakus, Ralf‐Dieter Hofheinz, Claus Röedel, Manish A. Shah, Mitsuru Sasako, Dietmar Lorenz, Jakob R. Izbicki, Wolf O. Bechstein, Hauke Lang, Stefan Paul Moenig - BMC Cancer 2017 被引用: 228

  10. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2020 被引用: 170

  11. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2024 被引用: 75

  12. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis

    著者: , , , , , - British journal of surgery 2014 被引用: 343

  13. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer

    著者: , , , , , , , , , , , , , , - British journal of surgery 2017 被引用: 115

  14. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial

    著者: , , , , , , , , , , , - European Journal of Cancer 2021 被引用: 65

  15. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers

    著者: , , , , , , - Gastric Cancer 2000 被引用: 1,800

  16. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma

    著者: , , , , , , , , , , , - Annals of Surgery 2016 被引用: 329

  17. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 41

  18. Randomised trials in surgery: problems and possible solutions

    著者: , , , , - BMJ 2002 被引用: 763

  19. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival

    著者: , , , , , , - Annals of Surgery 2016 被引用: 144

  20. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2019 被引用: 125

  21. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial

    著者: , , , , , , , - The Lancet Oncology 2006 被引用: 444

  22. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501)

    著者: , , , , , , , , , , , , , , , , - Gastric Cancer 2019 被引用: 127

  23. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2004 被引用: 923

  24. Increased DNA Methyltransferase 1 (DNMT1) Protein Expression Correlates Significantly with Poorer Tumor Differentiation and Frequent DNA Hypermethylation of Multiple CpG Islands in Gastric Cancers

    著者: , , , , , , , - American Journal Of Pathology 2004 被引用: 291